Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.3 NOK | -1.79% | +0.56% | +55.00% |
04-26 | Aker BioMarine AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-26 | Transcript : Aker BioMarine AS, Q1 2024 Earnings Call, Apr 26, 2024 |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company sustains low margins.
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 260.76 and 327.68 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company is highly valued given the cash flows generated by its activity.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Fishing & Farming
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+55.00% | 566M | B- | ||
+12.78% | 3.29B | B | ||
-95.58% | 1.61B | - | C+ | |
-0.48% | 1.61B | C | ||
-2.37% | 1.25B | D+ | ||
-2.40% | 1.22B | B | ||
-.--% | 1.22B | - | - | |
-11.54% | 1.21B | - | - | |
-10.44% | 1.2B | - | ||
0.00% | 1.19B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AKBM Stock
- Ratings Aker BioMarine